News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 190
- Sources here
- 16
- Companies here
- 16
Search results
Stored financial headlines
Active search
190 matching headlines
Ticker or company: KGMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Ginkgo Bioworks Q2 Earnings Call Highlights
Key Points Interested in Ginkgo Bioworks Holdings, Inc.? Here are five stocks we like better. Revenue fell sharply: Second-quarter 2026 revenue declined 48% year over year to $20 million, while net loss widened to $57 million and cash burn increased to $45 million. Ginkgo …
Sharemaestro market context Price above Trend Line 52 weeks -28.3% · Next-week setup negative 4.8%Kestrel Group Ltd GAAP EPS of -$1.03, revenue of $6.7M
* Kestrel Group Ltd press release [https://seekingalpha.com/pr/20611765-kestrel-group-reports-second-quarter-2026-financial-results] (KG [https://seekingalpha.com/symbol/KG]): Q2 GAAP EPS of -$1.03. * Revenue of $6.7M (+20.7% Y/Y). MORE ON KESTREL GROUP LTD * Financial information for Kestrel Group Ltd [https://seekingalpha.com/symbol/KG/income-statement]
KG
main company
Sharemaestro market context
Price below Trend Line
52 weeks -71.6%
Biosecurity sale shapes Ginkgo Bioworks (NYSE: DNA) Q2 2026 results
Ginkgo Bioworks reported a significant decrease in Q2 2026 revenue from continuing operations, down to $20.156 million from $39.134 million a year prior, primarily due to reduced program scope with key agriculture and pharmaceutical clients. Despite a sizable operating loss from continuing operations, the …
DNA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -45.9% · Next-week setup negative 42.3%
Merck KGaA (MKGAF) (Q2 2026) Earnings Call Highlights: Robust Growth and Raised Guidance Signal ...
This article first appeared on GuruFocus. Net Sales: Increased from EUR5,255 million in Q2 2025 to EUR5,434 million in Q2 2026, with organic sales growth of 4.1%. EBITDA pre: Increased from EUR1.46 billion to EUR1.6 billion, with organic growth of 9.3% and reported growth …
Sharemaestro market context Trend signal active 52 weeks +24.0%Henkel AG & Co KGaA (HELKF) (Q2 2026) Earnings Call Highlights: Strong Organic Growth and ...
This article first appeared on GuruFocus. Organic Sales Growth (Group): 3.2% in the first half of 2026, with pricing contributing 1.1% and volume contributing 2.1%. Reported Sales (Group): EUR10.3 billion, down 0.5% year-over-year, impacted by a nearly 4% negative foreign exchange effect. Adjusted EBIT …
Sharemaestro market context Trend signal active 52 weeks +6.7%Ginkgo Bioworks Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:DNA) 2026-08-06
Key Points Interested in Ginkgo Bioworks Holdings, Inc.? Here are five stocks we like better. Revenue fell sharply: Second-quarter 2026 revenue declined 48% year over year to $20 million, while net loss widened to $57 million and cash burn increased to $45 million. Ginkgo …
DNA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -45.9% · Next-week setup negative 42.3%
Earnings call transcript: Ginkgo Bioworks Q2 2026 revenue miss weighs on shares
Key Points Interested in Ginkgo Bioworks Holdings, Inc.? Here are five stocks we like better. Revenue fell sharply: Second-quarter 2026 revenue declined 48% year over year to $20 million, while net loss widened to $57 million and cash burn increased to $45 million. Ginkgo …
DNA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -45.9% · Next-week setup negative 42.3%
Fresenius SE & Co KGaA (FSNUY) (Q2 2026) Earnings Call Highlights: Raises Full-Year EPS ...
This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Fresenius SE & Co. KGaA (FSNUY) raised its full-year core EPS growth guidance to 10%-15% …
FRE
main company
Sharemaestro market context
Price above Trend Line
52 weeks +1.5% · Next-week setup positive 59.6%
Springer Nature AG & Co KGaA (SPGNY) (H1 2026) Earnings Call Highlights: Strong Growth and ...
This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Springer Nature AG & Co KGaA (SPGNY) delivered strong H1 2026 results with 6% underlying …
SPG
main company
Sharemaestro market context
Trend signal active
52 weeks -11.8% · Next-week setup negative 43.0%
HELLA GmbH & Co KGaA (HLLGY) (Q2 2026) Earnings Call Highlights: Electronics Strength ...
This article first appeared on GuruFocus. Revenue (Reported): EUR3.972 billion, broadly flat year-over-year (down 0.2%). Revenue (Organic): Grew 1.6% year-over-year at constant FX to EUR4.040 billion, outperforming global light vehicle production by 250 basis points. Electronics Sales: Up 6.6% year-over-year to EUR1.685 billion, driven …
HLE
main company
Sharemaestro market context
Price below Trend Line
52 weeks -17.7%
Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
U.S. FDA approves rituximab biosimilar candidate developed by Dr. Reddy's Laboratories (DRL), a biosimilar to Rituxan® (rituximab) Rituximab is a CD20-directed cytolytic antibody used across multiple oncology and immunology indications Approval expands Fresenius Kabi's U.S. biosimilars portfolio and reinforces its commitment to improving access …
FRE
main company
Sharemaestro market context
Price above Trend Line
52 weeks +1.5% · Next-week setup positive 59.6%
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
U.S. FDA and EMA acceptance for review of Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, of intravenous vedolizumab biosimilar candidate, an integrin receptor antagonist. Vedolizumab targets inflammatory bowel diseases, including moderately to severely active ulcerative colitis and Crohn's disease in adults. …
FRE
main company
Sharemaestro market context
Price above Trend Line
52 weeks +1.5% · Next-week setup positive 59.6%
Fresenius (XTRA:FRE) Stock May Still Be Cheap On Its 66% Run
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Fresenius SE KGaA has delivered a 65.9% return over the past three years, yet the stock still screens as undervalued on Simply Wall St's …
Sharemaestro market context Price above Trend Line 52 weeks +1.5% · Next-week setup positive 59.6%Ginkgo Bioworks (NYSE: DNA) awards RSUs to 10% owner
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has awarded 10% owner Barry Canton a total of 319,332 restricted stock units (RSUs) on July 28, 2026. These RSUs cover Class A Common Stock, with some vesting 75% on October 16, 2026, and 25% on January 21, …
Sharemaestro market context Price above Trend Line 52 weeks -28.3% · Next-week setup negative 4.8%Ginkgo Bioworks (DNA) CEO Jason R. Kelly receives over 300k new RSUs
Ginkgo Bioworks Holdings, Inc. CEO Jason R. Kelly was granted two awards of restricted stock units (RSUs) on July 28, 2026. One grant is for 74,258 RSUs, vesting 75% on October 16, 2026, and 25% on January 21, 2027. The second grant is for …
DNA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -45.9% · Next-week setup negative 42.3%